Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

ASRS Presidents' Retina Young Investigators Award, Advancing Insights Into Diabetic Eye Disease, Rishi P. Singh, MD
Rishi P. Singh, MD
Annual Meeting Talks
2018
Treatment Patterns and Vision Changes in Anti-VEGF Refractory Diabetic Macular Edema After Dexamethasone Implant in US Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2021
Episode 6: YAG Vitreolysis for Symptomatic Floaters with Dr. Chirag Shah
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: Diabetic Retinopathy

See more